Navigation Links
Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
Date:9/4/2012

SAN DIEGO, Sept. 4, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at four investor conferences during the first two weeks of September. These four corporate presentations will be webcast.

Friday, September 7th at 8:30 a.m Eastern Time: NewsMakers in the Biotech Industry Conference in New York City

Monday, September 10th at 11:15 a.m. Eastern Time: Rodman & Renshaw Annual Global Investment Conference in New York City

Wednesday, September 12th at 10:55 a.m. Eastern Time: Morgan Stanley Global Healthcare Conference in New York City

Thursday, September 13th at 1:45 p.m. London Time: Bank of America Merrill Lynch Global Healthcare Conference in London

To listen to the live webcast or a replay of the presentations, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after each event.

Additionally, on Wednesday, September 5th at 4:00 p.m. Eastern Time, Orexigen management will participate in a panel discussion at the Citi 7th Annual Biotech Day event. This event will not be webcast.

About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA.  The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial.  The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com

Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

WCG(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
2. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
3. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
4. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
5. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
6. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
7. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Global Markets for Animal Therapeutics and Diagnostics
10. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
11. Prime Therapeutics named exclusive pharmacy benefit manager for HR Policy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... , Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Joel Saban as president, effective Aug. 7, 2017. ... has decided to pursue other interests and will serve as ... tenure, Paul has served us in multiple leadership roles since ... in Jun. 2015 and has provided decisive, strategic leadership which ...
(Date:8/4/2017)... 4, 2017 The search for test results ... physician/patient consult has long been the goal of healthcare ... focus of the largest meeting of lab professionals and ... market research firm Kalorama Information.  The firm said scores ... or related supplies and software were at the American ...
(Date:8/2/2017)... AROMAS, Calif. , Aug. 2, 2017 /PRNewswire/ ... by Continental Who,s Who as a Pinnacle Lifetime ... currently the Key Account Manager at Turing Pharmaceuticals, ... communications, negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... “Covert Awakening”: Walid’s spiritual journey ... author, Julianne Hale, a consultant for the Intelligence Community. For more than ... the Near East region. Julianne has written hundreds of reports for the ...
(Date:8/22/2017)... ... August 22, 2017 , ... John Stewart joins Privis Health ... for t4 Leadership Development & Consulting. He has spent his career focusing on ... leadership development, servant leadership, data driven process improvement, and supportive technology. These key ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “Call Of ... Duty” is the creation of published author, C.S. Lizarde. Growing up on the ... untimely trials. When Carlos began to apply the Biblical keys to his life, ...
(Date:8/21/2017)... ... , ... PracticeMatch, a company that provides online resources , job ... practitioners like nurse practitioners and physician assistants , will conduct its ... year. The online career fairs will allow job seekers to connect with healthcare employers ...
(Date:8/21/2017)... ... August 22, 2017 , ... ... Stevens as a 2017-2018 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting more than ...
Breaking Medicine News(10 mins):